Ernexa Therapeutics近日宣布，其与美国食品药品监督管理局（FDA）举行的新药临床试验前（Pre-IND）会议取得圆满成功。此次会议为公司在卵巢癌领域开展首个人体试验扫清了关键监管障碍。
公司表示，基于FDA的积极反馈，团队正加速推进相关准备工作，朝着启动首次人体临床试验的目标稳步迈进。这一进展标志着Ernexa Therapeutics在卵巢癌创新疗法开发道路上迈出了重要一步。
Ernexa Therapeutics近日宣布，其与美国食品药品监督管理局（FDA）举行的新药临床试验前（Pre-IND）会议取得圆满成功。此次会议为公司在卵巢癌领域开展首个人体试验扫清了关键监管障碍。
公司表示，基于FDA的积极反馈，团队正加速推进相关准备工作，朝着启动首次人体临床试验的目标稳步迈进。这一进展标志着Ernexa Therapeutics在卵巢癌创新疗法开发道路上迈出了重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.